Article info

Download PDFPDF
Extended report
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Authors

  1. Correspondence to Dr Oliver Distler, Division of Rheumatology, University Hospital Zurich, Gloriastr. 25; Zurich 8091, Switzerland; Oliver.Distler{at}usz.ch
View Full Text

Citation

Jordan S, Distler JHW, Maurer B on behalf of the EUSTAR Rituximab study group, et al
Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Publication history

  • Received August 29, 2013
  • Revised December 12, 2013
  • Accepted December 27, 2013
  • First published January 17, 2014.
Online issue publication 
July 28, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.